Suzetrigine: A First-in-Class NaV1.8 Inhibitor – Mechanism and Clinical Trial Evidence for Acute Pain

Abstract

Pain management remains challenging due to opioid limitations and adverse effects. Suzetrigine is a novel, selective NaV1.8 sodium channel inhibitor developed as a non-opioid alternative for moderate-to-severe acute pain. This narrative review summarizes evidence on its mechanism of action, pharmacokinetics, clinical efficacy, safety profile, and regulatory status. Literature through March 2026 was reviewed from PubMed, Scopus, Google Scholar, and ClinicalTrials.gov. Clinical studies demonstrate Suzetrigine provides significant analgesic efficacy in acute post-operative pain with favorable tolerability. Common adverse effects – nausea, headache, constipation, and pruritus – were generally mild-to-moderate. However, benefit in chronic neuropathic pain appears limited. Suzetrigine received U.S. Food and Drug Administration approval in 2025 as the first oral selective NaV1.8 inhibitor for acute pain management, representing an important advancement in non-opioid analgesic therapy and a potential strategy to reduce opioid dependence.